Based on the Gerresheimer AG stock forecast from 0 analysts, the average analyst target price for Gerresheimer AG is not available over the next 12 months. Gerresheimer AG’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Gerresheimer AG is Slightly Bullish , which is based on 5 positive signals and 4 negative signals. At the last closing, Gerresheimer AG’s stock price was USD 19.00. Gerresheimer AG’s stock price has changed by -5.52% over the past week, -12.20% over the past month and -24.00% over the last year.
No recent analyst target price found for Gerresheimer AG
No recent average analyst rating found for Gerresheimer AG
Company Overview Gerresheimer AG
Gerresheimer AG, together with its subsidiaries, manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally. It operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The company offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and glass bottles and jars, as well as caps, closures, applicators, and accessories; development, industrialization and contract manufacturing of drug delivery programs; project and quality management; and drug delivery systems, including inhalers, injection/auto injectors, pen injectors, infusion systems, and inhalation assessment, autoinjector, and other services. It also provides diagnostic and medical devices comprising point-of-care tests, laboratory disposables, chemical and technical bottles, diagnostic and polymer vials, dropper bottles, PET bottles, and medical products comprising lancing devices, infusion sets, and disposable systems. In addition, the company offers cosmetic packaging solutions, such as moulded glass flacons and jars; tubular glass ampoules, droppers, samplers and vials; and plastic packaging products, as well as pharmaceutical, laboratory, and regulatory affairs services. It offers its products to pharmacy chains, supermarkets, and wholesalers. The company serves pharma, biotech, medical technology, diagnostics, cosmetics, glass containers, and food and beverage industries. Gerresheimer AG was founded in 1864 and is based in Düsseldorf, Germany. Read Less
Gerresheimer AG, together with its subsidiaries, manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally. It operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The compan...Read More
Frequently Asked Questions About Gerresheimer AG (GRRMY) Stock
Stock Target Advisor's fundamental analysis for Gerresheimer AG's stock is Slightly Bullish .
GRRMY stock's dividend yield is 1.16%.
Our analysis grades GRRMY stock's dividend yield at F. This means that GRRMY stock's dividend yield is above 45% of the stocks in the Medical Instruments & Supplies sector in the OTC exchange.
Based on this GRRMY may be a average dividend stock for its sector.
Unfortunately we do not have enough data on GRRMY's stock to indicate what its average analyst target is.
GRRMY stock's Price/Earning ratio is 31.51.
Our analysis grades GRRMY stock's Price / Earning ratio at B-. This means that GRRMY stock's Price/Earning ratio is above 18% of the stocks in the Medical Instruments & Supplies sector in the OTC exchange.
Based on this GRRMY may be undervalued for its sector.
The last closing price of GRRMY's stock was USD 19.00.
The most recent market capitalization for GRRMY is USD 3.96B.
Unfortunately we do not have enough analyst data on GRRMY's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Gerresheimer AG's stock.
As per our most recent records Gerresheimer AG has 11,913 Employees.
Gerresheimer AG's registered address is Klaus-Bungert-Strasse 4, Düsseldorf, Germany, 40468.
You can get more information about it from Gerresheimer AG's website at https://www.gerresheimer.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Gerresheimer AG (GRRMY) Stock
Stock Target Advisor's fundamental analysis for Gerresheimer AG's stock is Slightly Bullish .
GRRMY stock's dividend yield is 1.16%.
Our analysis grades GRRMY stock's dividend yield at F. This means that GRRMY stock's dividend yield is above 45% of the stocks in the Medical Instruments & Supplies sector in the OTC exchange.
Based on this GRRMY may be a average dividend stock for its sector.
Unfortunately we do not have enough data on GRRMY's stock to indicate what its average analyst target is.
GRRMY stock's Price/Earning ratio is 31.51.
Our analysis grades GRRMY stock's Price / Earning ratio at B-. This means that GRRMY stock's Price/Earning ratio is above 18% of the stocks in the Medical Instruments & Supplies sector in the OTC exchange.
Based on this GRRMY may be undervalued for its sector.
The last closing price of GRRMY's stock was USD 19.00.
The most recent market capitalization for GRRMY is USD 3.96B.
Unfortunately we do not have enough analyst data on GRRMY's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Gerresheimer AG's stock.
As per our most recent records Gerresheimer AG has 11,913 Employees.
Gerresheimer AG's registered address is Klaus-Bungert-Strasse 4, Düsseldorf, Germany, 40468.
You can get more information about it from Gerresheimer AG's website at https://www.gerresheimer.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for GRRMY !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
